Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: Preliminary findings of a phase II, single-arm study.

被引：0
|
作者：
Xu, Xiaojing
Yu, Yiyi
Wang, Yan
Cui, Yuehong
Li, Wei
Liang, Li
Li, Qian
Yu, Shan
Feng, Yi
Liu, Qing
Zhang, Pengfei
Lv, Minzhi
Liu, Tianshu
机构：
[1] Fudan Univ, Dept Oncol, Canc Ctr, Zhongshan Hosp, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Dept Biostat, Canc Ctr, Shanghai, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3566
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of first-line cetuximab plus FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study.
    Van Cutsem, Eric
    Kohne, Claus-Henning
    Folprecht, Gunnar
    Guenther, Silke
    Beier, Frank
    Papamichael, Demetris
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [22] Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer
    Kennecke, H.
    Chen, L.
    Blanke, C. D.
    Cheung, W. Y.
    Schaff, K.
    Speers, C.
    CURRENT ONCOLOGY, 2013, 20 (06) : 326 - 332
  • [23] Phase II single-arm study of palbociclib and cetuximab rechallenge in KRAS/NRAS/BRAF wild-type (KRAS WT) metastatic colorectal cancer (mCRC) patients (pts)
    Sorah, Jonathan D.
    Moore, Dominic T.
    Reilley, Matthew
    Salem, Mohamed E.
    Sanoff, Hanna Kelly
    Triglianos, Tammy
    McRee, Autumn Jackson
    Lee, Michael Sangmin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [24] Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study
    An, Jusheng
    Li, Xiumin
    Wang, Jing
    Zhu, Lijing
    An, Ruifang
    Jiang, Kui
    Huang, Yi
    Wang, Ke
    Li, Guiling
    Wang, Chunyan
    Yuan, Jianlin
    Hou, Xiaoli
    Yang, Guiyu
    Li, Jing
    Wang, Qingyu
    Zhu, Jun
    Wu, Lingying
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [25] Initial report of a phase I/II study of S-1 and irinotecan (IRIS) in combination with cetuximab in patients with wild-type RAS metastatic colorectal cancer
    Oki, E.
    Samura, H.
    Okumura, H.
    Ohchi, T.
    Orita, H.
    Kobayashi, K.
    Kinjo, T.
    Mori, S.
    Touyama, T.
    Ohgaki, K.
    Kawanaka, H.
    Makiyama, A.
    Ureshino, N.
    Kotaka, M.
    Shimose, T.
    Saeki, H.
    Nishimaki, T.
    Baba, H.
    Maehara, Y.
    ANNALS OF ONCOLOGY, 2018, 29 : 166 - 166
  • [26] Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial
    Kim, J. H.
    Kim, S. H.
    Jeon, M. K.
    Kim, J. E.
    Kim, K. H.
    Yun, K. -H.
    Jeung, H. -C.
    Rha, S. Y.
    Ahn, J. -H.
    Kim, H. S.
    ESMO OPEN, 2021, 6 (05)
  • [27] Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
    Gao, Ming
    Zhang, Xia
    Yan, Huan
    Zhao, Yan
    Yuan, Fang
    Sun, Decong
    Yang, Xuejiao
    Ju, Yanfang
    Wang, Lijie
    Tao, Haitao
    Tian, Luyuan
    Zhao, Changhong
    Ma, Junxun
    Hu, Yi
    Liu, Zhefeng
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [28] Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)
    Sakai, Daisuke
    Taniguchi, Hiroya
    Sugimoto, Naotoshi
    Tamura, Takao
    Nishina, Tomohiro
    Hara, Hiroki
    Esaki, Taito
    Denda, Tadamichi
    Sakamoto, Takeshi
    Okuda, Hiroyuki
    Satoh, Taroh
    Tsushima, Takahiro
    Makiyama, Akitaka
    Tsuda, Takashi
    Hosokawa, Ayumu
    Kuramochi, Hidekazu
    Tokunaga, Shinya
    Moriwaki, Toshikazu
    Yasui, Hisateru
    Ishida, Hiroyasu
    Tsuji, Akihito
    Otsu, Satoshi
    Shimokawa, Hozumi
    Baba, Eishi
    Sato, Mikio
    Matsumoto, Shigemi
    Ozaki, Yukinori
    Shinozaki, Katsunori
    Tamagawa, Hiroshi
    Goto, Masahiro
    Kadowaki, Shigenori
    Fujii, Hirofumi
    Koh, Yasuhiro
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Kishimoto, Junji
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 11 - 21
  • [29] A multicenter single arm phase II trial evaluating the safety and the efficacy of panitumumab and irinotecan for patients with NeoRAS wild-type metastatic colorectal cancer (C-PROWESS trial)
    Osumi, H.
    Ishizuka, N.
    Takashima, A.
    Kumekawa, Y.
    Nakano, D.
    Shiozawa, M.
    Denda, T.
    Sawada, R.
    Ouchi, K.
    Wakatsuki, T.
    Boku, N.
    Kato, K.
    Yamaguchi, K.
    Shinozaki, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S739 - S739
  • [30] Phase II study of cetuximab rechallenge in patients with ras wild-type metastatic colorectal cancer: E-rechallenge trial
    Osawa, H.
    Shinozaki, E.
    Nakamura, M.
    Ohhara, Y.
    Shindo, Y.
    Shiozawa, M.
    Uetake, H.
    Matsumoto, H.
    Ureshino, N.
    Satake, H.
    Kobayashi, T.
    Suto, T.
    Kitano, S.
    Ohashi, Y.
    Uemura, K.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2018, 29
12345